




# PHARMACEUTICAL 2023

CytomX Therapeutics Inc.  
Rank 354 of 446





# PHARMACEUTICAL 2023

CytomX Therapeutics Inc.  
Rank 354 of 446



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 28% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -81%, being 124% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	237,102
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	152,608
Liabilities, Non-Current	194,034
Other Assets	17,768
Other Compr. Net Income	252
Other Expenses	0
Other Liabilities	0
Other Net Income	2,018
Other Revenues	53,163
Property and Equipment	5,072
Research and Development	111,649
Selling, General and Administrative Expense	42,849

Output Variable	Value in 1000 USD
Assets	260,891
Liabilities	346,642
Expenses	154,498
Revenues	53,163
Stockholders Equity	-85,751
Net Income	-99,317
Comprehensive Net Income	-99,191
Economic Capital Ratio	-81%